AML Medical Science Liaison — Northeast Field Leader

IQVIA; Boston (MA); Presencial; USD 170 000 - 210 000; Tempo integral

Resumo da oferta

IQVIA is seeking experienced Medical Science Liaisons (MSLs) to support a late-stage AML program. This field-based role engages hematologists, oncologists, and other healthcare professionals to exchange scientific data and gather insights across AML treatment landscapes.

As a Medical Science Liaison, you will facilitate clinical and translational discussions, support medical affairs objectives, and travel up to 70% to designated territories with a focus on investigator-initiated studies and

Qualificações

• Advanced clinical or scientific degree from an accredited institution.
• Minimum of 4 years of MSL or relevant clinical experience in hematology/oncology.
• Minimum 3 years of hematology/oncology experience with therapeutic area expertise.
• Proven ability to communicate complex scientific information to diverse audiences.
• Proficiency with CRM, MS Office, Teams, and digital engagement tools.

Responsabilidades

• Develop and maintain scientific relationships with KOLs and investigators.
• Engage in compliant scientific discussions on AML, MRD, biomarkers, and standards of care.
• Communicate complex information clearly to physicians, researchers, and care teams.
• Support education programs, advisory boards, and investigator meetings.
• Document interactions and insights in the CRM system.

Conhecimentos

MSL experience

Scientific communication

Oncology/Hematology

CRM proficiency

Travel readiness

Formação académica

Advanced clinical or scientific degree

Ferramentas

CRM platforms

MS Office Suite

Microsoft Teams

Descrição da oferta de emprego

IQVIA is seeking experienced Medical Science Liaisons (MSLs) to support a late-stage AML program. This field-based role engages hematologists, oncologists, and other healthcare professionals to exchange scientific data and gather insights across AML treatment landscapes.

As a Medical Science Liaison, you will facilitate clinical and translational discussions, support medical affairs objectives, and travel up to 70% to designated territories with a focus on investigator-initiated studies and